Startups

Epsilogen

Develops antibody therapies for cancer using IgE, IgA and IgG antibody formats. Its lead MOv18 IgE program targets folate receptor alpha and is being studied in ovarian cancer.

Team

Alek SafarianDirector

Andrew CalamSVP of Clinical Operations

Cristina OlivaCMO

Elizabeth HardakerChief Translational Science Officer

Josep TaberneroClinical Adviser

Kevin FitzGeraldCSO

Leanne PartingtonVP of Product Development

Marianne BjørdalDirector

Marianne UtengDirector

Nick Robbins-CherryCFO

Nicoletta ColomboClinical Adviser

Peter FinanNon-Executive Chairman

Robert ColemanClinical Adviser

Sonia GulatiDirector

Susana BanerjeeClinical Adviser

Thomas HerzogClinical Adviser

Tim WilsonCEO

Investments

$6M2018-11-30	Christoph Ruedig
$—Unknown date	Epidarex Capital